Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Patients with positive interim PET/CT demonstrated poorer overall and progression-free survival compared with patients with negative interim PET/CT.
Researchers did not find a significant difference in survival outcomes for high- and low-risk patients with follicular lymphoma receiving immunotherapy.
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Survivors of NHL should be offered genetic counseling.
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
The investigational treatment was associated with a high rate of neurotoxicity.
Fewer patients who experienced late relapse received upfront rituximab compared with patients who experienced early relapse.
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Severe fatigue was more common in NHL survivors compared with the general population.
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
The model stratified patients into 3 risk groups based on median time to disease progression.
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Treatment for early-stage pediatric HL can include chemotherapy with or without radiotherapy, although use of radiotherapy is waning.
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.